UROGENITAL CANDIDIASIS: PROBLEMS OF THERAPY AND POSSIBILITIES OF THEIR CORRECTION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To carry out a systematic analysis of research data on the etiological structure of urogenital candidiasis at the present stage, on the resistance of Candida to antifungal drugs, and on the possibilities of antifungal therapy for acute and recurrent forms of the disease. Material and methods. The review includes the data of foreign and Russian articles published on this topic in the past 10 years and found in Pubmed and E-library. Results. The paper highlights the etiological structure of urogenital candidiasis and gives the basic principles of therapy for the disease. It presents the results of current investigations of antifungal resistance in Candida. There is evidence for the use of the antifungal drug Zalain (sertaconazole) in the therapy of urogenital candidiasis. The major pharmacokinetic characteristics and advantages of sertaconazole are shown. The results of the investigations demonstrating the high efficiency and safety of Zalain therapy for urogenital candidiasis, including its recurrent form, are presented. Conclusion. The species-specific heterogeneity of urogenital candidiasis pathogens is currently one of the causes of therapy failures because of the development of resistance in some fungal species, mainly non-albicans Candida ones. The current investigations have demonstrated the pronounced fungicidal effect of sertaconazole and the minimal number of posttherapy recurrences compared to that observed during standard therapy with imidazoles and triazoles. The high efficacy, convenient-to-use regimen, and no side effects of sertaconazole (Zalain) allow it to be recommended for the therapy of acute and recurrent urogenital candidiasis, including those caused by nonalbicans Candida species.

Full Text

Restricted Access

About the authors

Margarita R. Rakhmatulina

State Dermatovenereology and Cosmetology Research Center, Ministry of Health of Russia

Email: rahmatulina@cnikvi.ru
MD, associate professor, Deputy Director of research and clinical work Moscow 107076, Korolenko str. 3, bld. 6, Russia

Elena G. Tsoi

City Polyclinic Two Hundred and Nineteen, Moscow Healthcare Department

MD, dermatologist Moscow 125373, Yana Raydisa Boulevard 47, Russia

References

  1. Рэдклиф К. Европейские стандарты диагностики и лечения заболеваний, передаваемых половым путем. Пер. с англ. М.: Медицинская литература; 2006. 272с.
  2. Сергеев А.Ю., Сергеев Ю.В. Кандидоз. Природа инфекции, механизмы агрессии и защиты, лабораторная диагностика, клиника и лечение. М.: Триада-Х; 2001. 472с.
  3. Антипов М.С. Опыт терапии кандидозного вульвовагинита препаратом «Йодоксид». Гинекология. 2003; 5(5): 194-5.
  4. Sobel J.D. Pathogenesis of recurrent vulvovaginal candidiasis. Curr. Infect. Dis. Rep. 2002; 4(6): 514-9.
  5. Corsello S.A., Spinillo G., Osnengo C., Penna S., Guaschino A., Beltrame N. et al. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur. J. Obstet. Gynecol. Reprod. Biol. 2003; 110(1): 66-72.
  6. Holland J., Young M.L., Lee O., Chen S.C-A. Vulvovaginal carriage of yeasts other than Candida albicans. Sex. Transm. Infect. 2003; 79(3): 249-50.
  7. Richter S.S., Galask R.P., Messer S.A., Hollis R.J., Diekema D.J., Pfaller M.A. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J. Clin. Microbiol. 2005; 43(5): 2155-62.
  8. Vermitsky J.P., Self M.J., Chadwick S.G., Trama J.P., Adelson M.E., Mordechai E., Gygax S.E. Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection. J. Clin. Microbiol. 2008; 46(4): 1501-3.
  9. Arzeni D., Del Poeta M., Simonetti O., Offidani A.M., Lamura L., Balducci M. et al. Prevalence and antifungial susceptibility of vaginal yeasts in outpatients attending a gynecological center in Ancona, Italy. Eur. J. Epidimiol. 1997; 13(4): 447-50.
  10. Сергеев А.Ю., Маликов В.Е., Жарикова Н.Е. Этиология вагинального кандидоза и проблема устойчивости к антимикотикам. Сибирский журнал дерматологии и венерологии 2001; 1: 25-8.
  11. Анкирская А.С., Муравьева В.В., Фурсова С.А., Миронова Т.Г., Королева Т.Е. Мониторинг видового состава чувствительности к антимикотикам дрожжеподобных грибов, выделенных из влагалища женщин репродуктивного возраста. Клиническая микробиология и антимикробная химиотерапия 2006; 8(1): 87-95.
  12. Просовецкая А.Л. Кандидозный вульвовагинит: этиопатогенез и клиническое течение заболевания. Венеролог. 2006; 9: 14-9.
  13. Прилепская В.Н., Байрамова Г.Р. Вульвовагинальный кандидоз. Клиника, диагностика, принципы терапии. М.: ГЭОТАР-Медиа; 2010. 80с.
  14. Ribeiro M.A., Dietze R., Paula C.R., Da Matta D.A., Colombo A.L. Susceptibility profile of vaginal yeast isolates from Brazil. Mycopathologia. 2000; 151(1): 5-10.
  15. Sobel J.D., Wiesenfeld H.C., Martens M., Danna P., Hooton T.M., Rompalo A. et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N. Engl. J. Med. 2004; 351(9): 876-83.
  16. Sobel J.D., Zervos M., Reed B.D., Hooton T., Soper D., Nyirjesy P. et al. Fluconazole susceptibility of vaginal isolates obtained from woman with complicated Candida vaginitis: clinical implications. Antimicrob. Agents Chemother. 2003; 47(1): 34-8.
  17. Bauters T.G., Dhont M.A., Temmerman M.I., Nellis H.J. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am. J. Obstet. Gynecol. 2002; 187(3): 569-74.
  18. Agut J., Palacin C., Salgado J., Casas E., Sacristan A., Ortiz J.A. Direct membrane damaging effect of sertaconazole on Candida albicans as a mechanism of its fungicidal activity. Arzneimittelforschung. 1992; 42(5A): 721-4.
  19. Carrillo-Munoz A.J., Tur-Tur C., Giusiano G., Marcos-Arias C., Eraso E. Jauregizar N., Quindös G. Sertaconazole: an antifungal agent for the topical treatment of superficial candidiasis. Expert Rev. Anti Infect. Ther. 2013; 11(4): 347-58.
  20. Dellenbach P., Thomas J.L., Guerin V., Ochsenbein E., Contet-Audonneau N. Topical treatment of vaginal candidosis with sertaconazole and econazole sustained-release suppositories. Int. J. Gynaecol. Obstet. 2000; 71(Suppl.1): S47-52.
  21. Wang P.H., Chao H.T., Chen C.L., Yuan C.C. Single-dose sertaconazole vaginal tablet treatment of vulvovaginal candidiasis. J. Chin. Med. Assoc. 2006; 69(6): 259-63.
  22. Логутова Л.С., Гаспарян Н.Д., Горенкова О.С., Кручинина Е.В., Алимова Н.Г. Противорецидивный эффект различных антимикотических препаратов местного действия. Акушерство и гинекология. 2008; 3: 54-6.
  23. Серов В.Н. Проблема вульвовагинального кандидоза в гинекологической практике. Русский медицинский журнал. 2014; 22(6): 418-22.
  24. Hay P.E. Therapy of bacterial vaginosis. J. Antimicrob. Chemother. 1998; 41(1): 6-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies